Welcome to our dedicated page for Valneva Se SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE (VALN) is a French specialty vaccine company that reports to the U.S. Securities and Exchange Commission as a foreign private issuer. Its SEC filings, primarily on Form 20-F and Form 6-K, provide detailed insight into the company’s vaccine portfolio, segment reporting, financing arrangements and material agreements.
Through these filings, investors can review Valneva’s segment information, which distinguishes between Commercialized vaccines (including IXIARO/JESPECT, DUKORAL and IXCHIQ), Covid activities, Vaccine candidates and Technologies and services. Interim condensed consolidated financial statements filed on Form 6-K include revenue breakdowns by product groups, geographies and revenue types such as product sales, royalties, shipping and handling, milestone payments and other product-related income.
Valneva’s SEC reports also disclose key collaboration and financing structures. Examples include the amended collaboration and license agreement with Pfizer for the Lyme disease vaccine candidate VLA15, strategic partnership agreements related to chikungunya vaccine IXCHIQ, and loan agreements providing senior term loan facilities to refinance prior credit arrangements and fund general corporate and working capital requirements. These documents outline covenants, security interests over assets and intellectual property, and the role of subsidiaries that guarantee the company’s obligations.
On this page, Stock Titan surfaces Valneva’s latest SEC submissions as they are posted to EDGAR, including current reports on Form 6-K that furnish press releases, financial statements and business updates. AI-powered summaries help explain the key points of lengthy filings, such as changes in debt financing, updates to collaboration terms, or new clinical and regulatory disclosures. Users can quickly identify items related to vaccine segment performance, major agreements, and risk factor discussions without reading every page.
In addition to financial and operational information, Valneva’s filings may reference research tax credit arrangements, strategic partnerships with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI), and the structure of its international subsidiaries. This SEC filings page is designed to make those disclosures easier to navigate, with real-time updates and AI-generated highlights that point to the most relevant sections for vaccine-focused investors.
Valneva SE reports that it has voluntarily withdrawn the U.S. biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine IXCHIQ®. This follows the U.S. FDA’s earlier suspension of the IXCHIQ license in August 2025 and a more recent FDA decision to place the IND on clinical hold while it investigates a newly reported serious adverse event (SAE) from outside the U.S.
The SAE involved a younger adult who received three vaccines at the same time, including IXCHIQ; based on available data, the case may be plausibly related to IXCHIQ, but causality has not been determined. Valneva states that no IXCHIQ clinical studies are currently vaccinating participants and that it plans to continue post-marketing clinical activities after further discussions with regulators. The company continues to supply IXCHIQ in territories where it is licensed, including Europe, Canada, the United Kingdom and Brazil, and maintains that the vaccine’s benefit–risk profile remains favorable, particularly for people in endemic and outbreak settings.
Valneva SE filed a Form 6-K to furnish a press release announcing that its management will meet investors during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–14, 2026. The company plans one-on-one meetings with existing shareholders and discussions with other institutional specialist investors.
CEO Thomas Lingelbach and CFO Peter Bühler will present upcoming catalysts from Valneva’s clinical pipeline, including a pivotal data readout for its Lyme disease vaccine in the first half of the year, and will also discuss its commercial vaccine portfolio. Valneva describes itself as a specialty vaccine company with three proprietary travel vaccines on the market and a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a tetravalent Shigella vaccine candidate.
Valneva SE filed a Form 6-K reporting that it has released its results for the three months ended September 30, 2025. The company furnished a press release and unaudited interim condensed consolidated financial statements as exhibits, providing more detail on its recent quarterly performance.
Most of the information in this Form 6-K, excluding the section titled “Financial Outlook” in the press release, is incorporated by reference into Valneva’s existing Form F-3 registration statement. This means those disclosures can now be used in connection with Valneva’s registered securities offerings in the United States.
Valneva SE entered a senior term loan facility totaling
The Term Loans mature five years after each funding date, carry a fixed interest rate of
Valneva SE entered a senior term loan facility for an aggregate
Bpifrance Participations, EPIC Bpifrance, Bpifrance S.A., Caisse des d e9p f4ts et consignations (CDC) and CDC Croissance filed Amendment No. 3 to their Schedule 13D reporting positions in Valneva SE ordinary shares.
The filing shows Bpifrance Participations directly holds 8,639,886 ordinary shares and 17,259,364 voting rights; CDC Croissance holds 4,550,812 ordinary shares and voting rights. Aggregate voting rights reported for certain Reporting Persons are higher due to indirect holdings and joint ownership structures, with CDC reported as holding 21,810,176 voting rights. The percentages are calculated on 171,730,534 ordinary shares outstanding and 187,854,877 voting rights under U.S. law, producing a 9.2% voting-rights stake for Bpifrance Participations and an 11.6% voting-rights stake for CDC.
The Reporting Persons state the shares were acquired for investment purposes and that the apparent reduction in their percentage ownership results solely from an increase in outstanding shares, not from sales by the Reporting Persons. No reportable transactions occurred in the last 60 days and no plans currently exist for the corporate actions listed in Schedule 13D instructions, though they reserve the right to change investment intent.
FAQ
What is the current stock price of Valneva Se (VALN)?
What is the market cap of Valneva Se (VALN)?
